Resolution of secondary hemophagocytic lymphohistiocytosis after treatment with the JAK1/2 inhibitor ruxolitinib.

ABSTRACT:

SUBMITTER: Goldsmith SR 

PROVIDER: S-EPMC6963250 | biostudies-literature | 2019 Dec

REPOSITORIES: biostudies-literature